Edition:
United States

Summit Therapeutics PLC (SMMT.OQ)

SMMT.OQ on NASDAQ Stock Exchange Global Market

10.26USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$10.26
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
7,388
52-wk High
$16.59
52-wk Low
$7.95

Select another date:

Wed, Oct 4 2017

BRIEF-Summit highlights DMD biomarker phase 2 clinical trial data in presentations at 22nd WMS Congress

* Summit highlights DMD biomarker validation data and phase 2 clinical trial baseline characteristics in presentations at 22nd WMS Congress

BRIEF-Summit Therapeutics announces pricing of public offering $12.00 per ADS

* Summit Therapeutics announces pricing of public offering of 1,459,000 American Depositary Shares

BRIEF-Summit Therapeutics announces proposed public offering of $15 mln of American Depositary shares

* Summit Therapeutics announces proposed public offering of $15.0 million of American Depositary shares Source text for Eikon: Further company coverage:

BRIEF-Summit awarded BARDA contract worth up to $62 million

* Summit awarded BARDA contract worth up to $62 million to support the development of ridinilazole for the treatment of C. difficile infection

BRIEF-Summit announces positive top-line data from an exploratory phase 2 supporting Ridinilazole

* Summit announces positive top-line data from an exploratory phase 2 clinical trial supporting Ridinilazole as a highly selective antibiotic for the treatment of CDI

BRIEF-Summit Therapeutics reports financial results for Q2 ended July 31 2017

* Summit Therapeutics reports financial results for the second quarter and half year ended July 31 2017 and operational progress

Select another date: